Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Arca Biopharma Inc (ABIO)

Arca Biopharma Inc (ABIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arca Biopharma Inc 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 USA

P: 720-940-2200

Description:

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products. The Company's business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.

Key Statistics

Overview:

Market Capitalization, $K 39,057
Shares Outstanding, K 9,321
Annual Sales, $ 0 K
Annual Net Income, $ -5,480 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,990 K
60-Month Beta 2.86
% of Insider Shareholders 0.53%
% of Institutional Shareholders 4.32%
Float, K 9,272
% Float 99.47%

Growth:

1-Year Return -21.39%
3-Year Return -81.38%
5-Year Return -95.61%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 99.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 11/04/20
Earnings Per Share ttm -2.58
EPS Growth vs. Prev Qtr 54.79%
EPS Growth vs. Prev Year 56.58%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00
Most Recent Split 1-18 on 04/04/19

ABIO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward 0.00
Price/Earnings to Growth N/A
Return-on-Equity % -31.28%
Return-on-Assets % -29.34%
Profit Margin % 0.00
Net Margin % N/A
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.79
Book Value/Share 5.41
Interest Coverage -564.00
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar